Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
PD1 and PDL1 inhibitors (in short, PDx) have revolutionized cancer care since the approval of pembrolizumab for melanoma in 2014. Since then, the field has expanded both in terms of the number of approved PDx and the range of indications. However, despite this dramatic progress, a portion of patients across malignancies do not respond or develop resistance to treatment. Over the past few years, the field has faced the challenge of finding novel therapy combinations that can increase the efficacy of PDx in these patients.
